483
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA 483, Jul 18, 2025
Record Details
An FDA inspection of Celgene Corporation in Summit, NJ, revealed significant deficiencies in the manufacturing of sterile drug products, Breyanzi and Abecma. Observations included failures in aseptic processing procedures, inadequate environmental monitoring, and insufficient investigation of discrepancies. The facility also exhibited issues with building maintenance and equipment qualification, indicating a lack of control over critical manufacturing processes.
View Company Profile
ID · 3f16d573-7ac8-419f-9ff4-2b070cead434
Other documents for Bristol-Myers Squibb Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.